Swiss injectable giant opens Miami operations amid U.S. plastic surgery boom.
Galderma has established operations in Miami, positioning itself at the epicenter of U.S. aesthetic surgery and injectable demand. The move reflects a deliberate geographic strategy: Miami's plastic surgery density, high-income patient base, and concentration of independent practices and DSOs make it a natural hub for direct-to-practice engagement and clinical education.
Galderma's U.S. portfolio—Restylane, Restylane Volyme, Dysport—competes directly against Allergan Aesthetics' Botox and Juvéderm lines. Miami expansion allows the company to deepen relationships with high-volume injectors and surgeons, run clinical events, and accelerate adoption of newer products like Volyme in temple and cheek augmentation. The company has also signaled intent to expand its product range beyond current offerings.
Miami's plastic surgery density and high-income patient base make it a natural hub for direct engagement.
For independent practices, this signals competitive intensity. Galderma's direct presence typically means more aggressive rebate structures, loyalty programs, and clinical support. Practices should audit current Allergan/Galderma spend and rebate terms to ensure they are capturing available incentives.
Source: original report ↗
Frequently asked questions
Why is Galderma opening an office in Miami?
Miami has the highest concentration of plastic surgeons and independent aesthetic practices in the U.S., combined with a high-income patient base. Galderma's Miami operations enable direct engagement with high-volume injectors, clinical education events, and faster adoption of products like Restylane Volyme for temple and cheek augmentation.
What products does Galderma offer to compete with Botox and Juvéderm?
Galderma's U.S. aesthetic portfolio includes Restylane, Restylane Volyme, and Dysport. These products directly compete against Allergan Aesthetics' Botox and Juvéderm lines for injectable demand in the U.S. market.
How does Galderma's Miami expansion affect independent practices?
Galderma's direct presence typically triggers more aggressive rebate structures, loyalty programs, and clinical support offerings. Independent practices should review their current Allergan and Galderma spend and rebate terms to ensure they're capturing all available incentives and negotiating competitively.
What is Restylane Volyme used for?
Restylane Volyme is designed for temple and cheek augmentation, providing volume restoration in these facial areas. It's one of Galderma's newer products that the company is accelerating adoption of through its Miami clinical education efforts.
Will Galderma launch new aesthetic products beyond Restylane and Dysport?
Yes, Galderma has signaled intent to expand its product range beyond its current U.S. offerings of Restylane, Restylane Volyme, and Dysport. The company's Miami expansion supports the infrastructure needed to introduce and educate practices on these new products.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
